FocalTherics (NASDAQ:FOCL) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of FocalTherics (NASDAQ:FOCL) to a hold rating in a research note issued to investors on Saturday.

A number of other analysts also recently weighed in on FOCL. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of FocalTherics in a research report on Tuesday, June 2nd. Mizuho set a $15.00 price target on shares of FocalTherics and gave the company an “outperform” rating in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.00.

FocalTherics Stock Down 0.3%

NASDAQ FOCL opened at $6.12 on Friday. The company has a market capitalization of $229.38 million, a price-to-earnings ratio of -7.56 and a beta of -0.04. The company’s 50 day moving average price is $5.24. FocalTherics has a twelve month low of $1.21 and a twelve month high of $6.36. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79.

FocalTherics (NASDAQ:FOCL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $20.48 million during the quarter, compared to the consensus estimate of $19.46 million. FocalTherics had a negative return on equity of 137.61% and a negative net margin of 41.47%. On average, research analysts anticipate that FocalTherics will post -0.78 earnings per share for the current year.

Insider Transactions at FocalTherics

In related news, Director Joshua Levine acquired 10,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $4.22 per share, for a total transaction of $42,200.00. Following the completion of the transaction, the director directly owned 35,000 shares in the company, valued at approximately $147,700. This trade represents a 40.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.10% of the company’s stock.

Institutional Trading of FocalTherics

Large investors have recently added to or reduced their stakes in the business. Flax Pond Capital LLC bought a new position in shares of FocalTherics in the fourth quarter worth approximately $2,623,000. Rock Springs Capital Management LP raised its position in shares of FocalTherics by 7.1% during the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after purchasing an additional 91,500 shares during the period. Kovack Advisors Inc. bought a new stake in shares of FocalTherics during the 4th quarter valued at $53,000. Lido Advisors LLC purchased a new position in shares of FocalTherics during the 1st quarter valued at $40,000. Finally, SmartHarvest Portfolios LLC purchased a new position in shares of FocalTherics during the 1st quarter valued at $38,000. 62.74% of the stock is currently owned by institutional investors.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.